Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Eisai To Resubmit Aricept Severe Alzheimer’s sNDA In December

This article was originally published in The Pink Sheet Daily

Executive Summary

Firm is considering changing from paper to electronic filing to resolve formatting issues behind FDA’s refusal to file the sNDA.
Advertisement

Related Content

Alzheimer’s Drugs Should Be Limited To Moderate Disease, U.K.’s NICE Says
Alzheimer’s Drugs Should Be Limited To Moderate Disease, U.K.’s NICE Says
Eisai Resubmits Aricept sNDA For Severe Alzheimer’s
Eisai Resubmits Aricept sNDA For Severe Alzheimer’s
Eisai Rufinamide Electronic Resubmission Aims To Make NDA More Accessible
Eisai Rufinamide Electronic Resubmission Aims To Make NDA More Accessible
Forest’s Namenda Gets “Not Approvable” Letter For Mild Alzheimer’s Indication
Forest’s Namenda Gets “Not Approvable” Letter For Mild Alzheimer’s Indication
FDA Extends Agilect User Fee Deadline Due To “Technical Error”

Topics

Advertisement
UsernamePublicRestriction

Register

PS061184

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel